Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Glucocorticoids+MMF

Phase 3Small molecule

RRuijin Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrence Free SurvivalRecruiting

Recurrence Free SurvivalPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Recurrence Free Survival

NCT06468709

Clinical

Trials by Indication[1]

Recurrence Free Survival1 trial

A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence

Recruiting·RRuijin Hospital·Phase 4·NCT06468709·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Glucocorticoids+MMF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucocorticoids+MMF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucocorticoids+MMF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRuijin Hospital

Related News